Pills are keeping abortion accessible even where it’s banned. A court is considering restrictions

PUBLISHED Sep 9, 2026, 12:09 PM ET

A panel of federal judges heard oral arguments regarding whether prescribing regulations should be tightened for mifepristone, a primary medication used in U.S. abortion procedures. The case, brought before the New Orleans-based 5th U.S. Circuit Court of Appeals by Louisiana Attorney General Liz Murrill and co-plaintiff Rosalie Markezich, represents one of multiple ongoing legal challenges seeking to restrict healthcare providers in states where abortion remains legal from shipping abortion pills into states with active bans. The U.S. Food and Drug Administration stated it is conducting an independent regulatory review of current dispensing protocols. Medication abortion accounts for at least three in five procedures nationwide, serving as a critical access route following the Supreme Court decision returning regulatory authority to individual states. The ongoing litigation unfolds during a midterm election cycle, with the core constitutional and regulatory questions ultimately expected to reach the U.S. Supreme Court for final resolution.

By James Porter | JQJO News

Media Bias

Articles Published:: 37
Right Leaning:: 4
Left Leaning:: 4
Neutral:: 29

Explain Framing

Left: Emphasizes threats to reproductive healthcare access and judicial activism. Center: Focuses objectively on legal arguments and potential Supreme Court review. Right: Highlights concerns over federal overreach and enforcement of state bans.